Leading authority in developmental-behavioral pediatrics serves as a pivotal guide to the Digital Health innovator to accelerate the adoption of objective, eye-tracking screening tools in primary care. BOSTON, Jan. 6, 2026 /PRNewswire/ -- EyeContactDX, a pioneering Digital Health company transforming early autism spectrum disorder (ASD) detection, today announced the strategic engagement of Dr. Carol Weitzman as Senior Strategic Advisor. Dr. Weitzman, a globally recognized leader in Developmenta

PALO ALTO, Calif., Jan. 6, 2026 /PRNewswire/ -- Segmed, Inc., a leader in real world medical imaging data for research and AI development, today announced that it has secured an independent Expert Determination confirming that its structured clinical data, medical imaging pixels, and radiology text meet the HIPAA de-identification standard. Continue Reading A unified de-identification pipeline for clinical data and medical imaging — HIPAA compliant by design. Expert Determination is one of the t

The Fund Will be Managed by Experienced Life Sciences Investor Nishant Rastogi NEW YORK, Jan. 6, 2026 /PRNewswire/ -- Today, the Lupus Research Alliance, the world's largest private funder of lupus research, announced the formation of a new philanthropic venture fund Lupus Ventures. The Fund is dedicated to advancing treatments and diagnostics for systemic lupus erythematosus (SLE), its manifestations, and related autoimmune conditions. Continue Reading Lupus Ventures aims to accelerate the deve

Groundbreaking code will facilitate use, adoption, and pathway for reimbursement of AI-based hemodynamic assessment, including Sensydia's Cardiac Performance System (CPS™). LOS ANGELES, Jan. 6, 2026 /PRNewswire/ -- Sensydia, a medical technology company advancing non-invasive cardiac assessment, today announced that the American Medical Association (AMA) has published a new industry-first Category III CPT® code, 1036T, for noninvasive augmentative AI hemodynamic assessment, encompassing Sensydia

TOKYO, Jan. 6, 2026 /PRNewswire/ -- Yonalink and PSP today announced a strategic collaboration aimed at simplifying the integration of medical information stored in Electronic Health Records (EHRs) into Electronic Data Capture (EDC) systems used in clinical trials. This initiative is designed to enhance operational efficiency and expand opportunities for global clinical trials conducted in Japan. PSP will leverage its advanced medical information management technologies developed through its clo

– As presented later this week at the ASCO GI conference, the large case-control validation study of nearly 1,000 samples highlights a head-to-head comparison with the test's first version, which is currently under FDA review – – Assay upgrades led to improved detection rates, limit of detection and signal-to-noise ratio – BRISBANE, Calif., Jan. 6, 2026 /PRNewswire/ -- Freenome, an early cancer detection company developing blood-based screening tests, today is reporting the improved clinical pe

Partnership focuses on delivering high-quality medical education to improve rare disease patient outcomes BOSTON and WASHINGTON, Jan. 6, 2026 /PRNewswire/ -- Medlive is proud to announce that the National Organization for Rare Disorders has again selected the company as its official Continuing Medical Education (CME) partner. This renewed commitment reflects the organizations' shared mission to expand access to rare disease education, equip clinicians with the tools to shorten time to diagnosis

EDINBURGH, Scotland, TORONTO and EDMONTON, AB, Jan. 6, 2026 /PRNewswire/ -- Chromatin Bioscience, Mediphage Bioceuticals, and Entos Pharmaceuticals are pleased to announce they are receiving advisory services and funding from the competitive, transatlantic, UKRI Innovate UK and the National Research Council of Canada Industrial Research Assistance Program (NRC IRAP) collaborative innovation program. This supports strategic partnership to develop next-generation therapeutics by combining the Chro

New Lenses Combine Advanced Silicone Hydrogel Material with Proven ActivControl® Technology*1 to Slow the Worsening of Myopia in Children†2,3 FAREHAM, England, Jan. 6, 2026 /PRNewswire/ -- CooperVision today announced the forthcoming launch of MyDay® MiSight® 1 day contact lenses in the UK and select European and surrounding markets, expanding its evidence-based myopia management portfolio. This new myopia control soft contact lens combines the proven MiSight® 1 day ActivControl® Technology with

FORZINITY™ now commercially available following U.S. Food and Drug Administration (FDA) accelerated approval for Barth syndrome (BTHS) FDA engagement planned to advance development for younger BTHS and primary mitochondrial disease (PMD) patients; dry age-related macular degeneration (AMD) development efforts progressing NEEDHAM, Mass., Jan. 6, 2026 /PRNewswire/ -- Stealth BioTherapeutics Inc. (the "Company" or "Stealth"), a commercial-stage biotechnology company focused on the discovery, devel